Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
VACCINE RESEARCH

Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines

Jason B. Alarcon, Andrea Waterston Hartley, Noel G. Harvey, John A. Mikszta
Jason B. Alarcon
BD Technologies, Research Triangle Park, North Carolina 27709
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Waterston Hartley
BD Technologies, Research Triangle Park, North Carolina 27709
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noel G. Harvey
BD Technologies, Research Triangle Park, North Carolina 27709
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Mikszta
BD Technologies, Research Triangle Park, North Carolina 27709
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: john_mikszta@bd.com
DOI: 10.1128/CVI.00387-06
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Comparison of standard 27-Ga needle to 34-Ga microneedle. The displayed microneedle has an inner diameter of 76 μm, an outer diameter of 178 μm, and a total exposed length of 1.0 mm.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Serum antibody response in rats (n = 4 per group) following immunization with 1, 0.1, or 0.01 μg of whole inactivated influenza virus A/PR/8/34 on days 0, 21, and 42. Influenza virus-specific antibodies were measured by ELISA on (A) day 21, (B) day 42, and (C) day 56. Displayed are ELISA GMTs ± standard deviation.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Rats (n = 10 per group) were immunized with either a high dose (100 μl of undiluted vaccine) or a low dose (100 μl of vaccine diluted 1:10) of trivalent split-virion influenza vaccine (Fluzone 2003-2004 formulation) and analyzed for serum antibody response 21 days later. Bars represent group GMT, and open symbols represent the responses from individual animals. (A) ELISA response against the H1N1 (A/NC/20/99) strain. (B) HAI response against the H1N1 (A/NC/20/99) strain. (C) ELISA response against the H3N2 (A/Pan/2007/99) strain. (D) HAI response against the H3N2 (A/Pan/2007/99) strain. (E) ELISA response against the B (B/HK/1434/02) strain. Due to insufficient quantities of sera from some animals, for analysis of ELISA titers against the B strain, only seven individuals from the i.d. “low-dose” group and nine animals from the i.m. “low-dose” group were analyzed. (F) HAI response against the B (B/HK/1434/02) strain.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Luciferase activity in skin or muscle following i.d. or i.m. administration of either 50 μg or 5 μg of pCMV-Luc (n = 4 rats per group). As a negative control, rats were injected with the unrelated reporter plasmid, pCMV-β. Tissues were collected 24 h postdelivery and analyzed by luciferase assay for reporter gene expression. Luciferase activity is expressed as mean increase in RLU over background luciferase activity from tissue sites that had been injected with pCMV-β. Bars represent group means, and open symbols represent responses from individual animals.

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Serum antibody response in rats (n = 5 per group) following immunization with 50, 10, 5, or 1 μg of pCMV-HA on days 0, 21, and 42. Antibodies against whole inactivated influenza virus A/PR/8/34 were measured by ELISA on (A) day 21, (B) day 42, and (C) day 56. Displayed are ELISA GMTs ± standard deviation.

PreviousNext
Back to top
Download PDF
Citation Tools
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines
Jason B. Alarcon, Andrea Waterston Hartley, Noel G. Harvey, John A. Mikszta
Clinical and Vaccine Immunology Apr 2007, 14 (4) 375-381; DOI: 10.1128/CVI.00387-06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines
Jason B. Alarcon, Andrea Waterston Hartley, Noel G. Harvey, John A. Mikszta
Clinical and Vaccine Immunology Apr 2007, 14 (4) 375-381; DOI: 10.1128/CVI.00387-06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

influenza vaccines
Needles
Vaccination

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X